The Economic Footprint of Selected Pharmaceutical Companies in Europe
The research study, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA), investigates the direct economic impact of seven selected companies of the pharmaceutical industry in Europe as well as their contribution to the entire European economy from 2010 to 2014. In addition to direct gross value added (GVA) and employment effects, the Economic Footprint also accounts for indirect and induced economic effects (so-called spillover effects) along the companies’ supply chains. Thus, for every direct employee the companies supported almost five additional jobs within the European economy. The seven investigated companies – Abbvie, AstraZeneca, Boehringer Ingelheim, Ipsen, Janssen (J&J), Novartis and Sanofi – together accounted for €34.6 billion of direct GVA and generated additional €43.3 billion as spillover effects along their supply chains in Europe. In addition, they already surpassed the European Union’s 2020 strategy’s target R&D intensity rate of 3% by a factor of almost six, showing their importance for innovation in Europe.
National Health Account for Germany
Within the scope of this research project commissioned by the Federal Ministry for Economic Affairs and Energy, the health industries in Germany are identified as an economic sector with its contribution to value added and labour force, as well as to foreign trade. By linking together all previously created compilations for the German health economy, commissioned by the Federal Ministry for Economic Affairs a comprehensive tool of National Health Accounts (NHA) has been developed which is increasingly used to answer health and economic policy issues. Furthermore, data structures of NHA now use the new classification of economic activities (NACE Rev. 2) and are adjusted to the updated compilation methods of the System of National Accounts (SNA).
The Economic Footprint of the Cluster Life Science Nord
How is the Life Science Nord Cluster positioned? How much economic strength does the industry have in Hamburg and Schleswig-Holstein? Life Science Nord commissioned this study to obtain indicators on these and further questions.The health industry is analyzed as the cluster’s core. The health industry covers companies that produce and sell (including wholesale) human pharmaceuticals, medical technology, personal care and dental hygiene products, sports and fitness equipment, health-relevant information and communication technology, and data processing devices.The economic research institute WifOR has applied the established “economic footprint” approach across both Hamburgand Schleswig-Holstein and for the first time described the close economic ties between the two states in an analysis of the health industry. Besides determining the key economic indicators for the entire industry, it also carried out an analysis that focused exclusively on the Life Science Nord Cluster.
The Economic Footprint of the Pharmaceutical Industry
With the present research project the pharmaceutical industry’s direct economic effects are enhanced by a regional breakdown and a differentiation between economic effects by originators and generics. For this purpose the global economic effects are divided into the continental effects for Africa, Latin and Northern America, Asia, Europe and Oceania according to the geographical regions of the UN. Therefore the global economic effects have been updated in a first step as well. Additionally to the regional quantification an initial assessment of the economic effects differentiated by originators and generics in the pharmaceutical industry is given.The update of the pharmaceutical industry’s economic effects and the regional breakdown are based on statistics of official organizations such as the UNSD, the OECD and Eurostat. The available data was the limiting factor for the differentiation between originators and generics: available data displays primarily figures like the production volume and sales for generics and originators. Since the assessment of the economic effects is based on macroeconomic indicators, assumptions had to be made in order to use the available information for a first estimation of the economic effects differentiated by originators and generics.
The Social Impact of medical innovations
With the study ‘The Social Impact of medical innovations’ WifOR identifies - using the example of the pharmaceutical Entresto® - social and economic outcomes that result from the life-prolonging effect of the medicine. The impact study shows that there exist important dimensions of medical progress that go beyond the early benefit assessment (as in the AMNOG process). The study was commissioned by Novartis Pharma GmbH.
Click here to view and download the Management Summary.
Workshop „Education, Health and Labor Market Outcomes"
The WifOR-Workshop took place in Darmstadt from October 8.-9. Keynote Lectures were given by Hans-Martin von Gaudecker (Bonn) and Patrick Puhani (Hannover). About 30 interdisciplinary researchers from the fields of education, health and labor economics as well as (economic) sociology and psychology discussed on the interactions of education, health and labor market outcome. Further members of the academic committee were Thomas Rigotti (Mainz), Christiane Gross (Hannover) and Andrea Mühlenweg (WifOR).
Click here to view and download the Workshop Program.
- WifOR und BIHK e.V. stellen Zuwanderungsstudie vor.
- Neue Studie zur volkswirtschaftlichen Bedeutung der pharmazeutischen
Industrie: The Economic Footprint of the Pharmaceutical Industry – Download von
Studie und Key Findings.
- Weiterentwicklung des deutschen Gesundheitssatellitenkontos zu einer Gesundheitswirtschaftlichen Gesamtrechnung: Abschlussbericht.
- Vom Gesundheitssatellitenkonto zur Gesundheitswirtschaftlichen Gesamtrechnung. Ergebnisse des Forschungsprojekts im Auftrag des BMWi.
WifOR in the media
[German and English News]